应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。
关闭
06078 海吉亚医疗
未开盘 03-25 16:08:03
14.040
-0.380
-2.64%
最高
14.420
最低
13.960
成交量
374.08万
今开
14.420
昨收
14.420
日振幅
3.19%
总市值
87.33亿
流通市值
87.33亿
总股本
6.22亿
成交额
5,268万
换手率
0.60%
流通股本
6.22亿
市净率
--
ROE
--
每股收益
0.00
52周最高
--
52周最低
--
市盈率
--
股息
--
股息收益率
--
ROA
--
分时
五日
日K
周K
月K
数据加载中...
北京优虎网络科技有限公司
免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）
资讯
新帖
简况
云顶新耀：新型mRNA个性化肿瘤治疗性疫苗EVM16完成首例患者给药
证券日报 · 03-11
云顶新耀：新型mRNA个性化肿瘤治疗性疫苗EVM16完成首例患者给药
海吉亚医疗盘中异动 下午盘大幅下挫5.04%报15.080港元
市场透视 · 03-07
海吉亚医疗盘中异动 下午盘大幅下挫5.04%报15.080港元
富达国际减持海吉亚医疗(06078)113.48万股 每股作价约16.83港元
智通财经 · 03-06
富达国际减持海吉亚医疗(06078)113.48万股 每股作价约16.83港元
云顶新耀首款AI驱动的自研mRNA肿瘤治疗性疫苗完成首例患者给药
人民财讯 · 03-06
云顶新耀首款AI驱动的自研mRNA肿瘤治疗性疫苗完成首例患者给药
云顶新耀(01952)宣布首款自主研发的新型mRNA个性化肿瘤治疗性疫苗EVM16完成首例患者给药
智通财经 · 03-06
云顶新耀(01952)宣布首款自主研发的新型mRNA个性化肿瘤治疗性疫苗EVM16完成首例患者给药
海吉亚医疗盘中异动 股价大涨5.04%
市场透视 · 03-06
海吉亚医疗盘中异动 股价大涨5.04%
我国科研团队提出人工合成细菌治疗肿瘤新方法
美港电讯 · 03-04
我国科研团队提出人工合成细菌治疗肿瘤新方法
海吉亚医疗盘中异动 快速拉升5.01%
市场透视 · 03-03
海吉亚医疗盘中异动 快速拉升5.01%
港股异动 | 海吉亚医疗(06078)再跌超7% 机构预计公司24年下半年销售收入或逊于市场预期
智通财经 · 02-28
港股异动 | 海吉亚医疗(06078)再跌超7% 机构预计公司24年下半年销售收入或逊于市场预期
海吉亚医疗盘中异动 早盘快速下跌5.05%
市场透视 · 02-28
海吉亚医疗盘中异动 早盘快速下跌5.05%
【首个自研ADC澳洲临床入组 康方生物IO 2+ADC战略再进一步】近日，康方生物宣布，公司自主研发的差异化靶向人表皮生长因子受体3（HER3）ADC新药AK138D1，治疗晚期恶性肿瘤的I期临床研究在澳洲完成首例受试者入组。AK138D1是康方生物首个进入临床阶段的ADC药物。ADC药物是康方生物在全球范围内重塑治疗格局，构建肿瘤治疗新标准，以创新疗法造福全球患者的重要力量，也是康方生物推进“IO 2.0+ADC”战略的重要抓手。目前康方生物自主研发的全球首创双抗新药卡度尼利（PD-1/CTLA-4双抗）和依沃西（PD-1/VEGF双抗）均已获批上市。康方生物是全球唯一拥有2个肿瘤免疫治疗双抗的制药公司，在IO+ADC联合战略中已经建立了在肿瘤免疫端的全球领先优势。AK138D1等差异化ADC药物的开发，为康方生物充分挖掘创新产品组合的临床价值，持续迭代肿瘤疗法开拓了更广阔的空间。
金融界 · 02-27
【首个自研ADC澳洲临床入组 康方生物IO 2+ADC战略再进一步】近日，康方生物宣布，公司自主研发的差异化靶向人表皮生长因子受体3（HER3）ADC新药AK138D1，治疗晚期恶性肿瘤的I期临床研究在澳洲完成首例受试者入组。AK138D1是康方生物首个进入临床阶段的ADC药物。ADC药物是康方生物在全球范围内重塑治疗格局，构建肿瘤治疗新标准，以创新疗法造福全球患者的重要力量，也是康方生物推进“IO 2.0+ADC”战略的重要抓手。目前康方生物自主研发的全球首创双抗新药卡度尼利（PD-1/CTLA-4双抗）和依沃西（PD-1/VEGF双抗）均已获批上市。康方生物是全球唯一拥有2个肿瘤免疫治疗双抗的制药公司，在IO+ADC联合战略中已经建立了在肿瘤免疫端的全球领先优势。AK138D1等差异化ADC药物的开发，为康方生物充分挖掘创新产品组合的临床价值，持续迭代肿瘤疗法开拓了更广阔的空间。
【港股异动 | 海吉亚医疗(06078.HK)跌逾3% 】海吉亚医疗(06078.HK)跌逾3%。截至发稿，跌2.36%，报16.52港元，成交额1595.27万港元。
金融界 · 02-25
【港股异动 | 海吉亚医疗(06078.HK)跌逾3% 】海吉亚医疗(06078.HK)跌逾3%。截至发稿，跌2.36%，报16.52港元，成交额1595.27万港元。
港股异动 | 海吉亚医疗(06078)跌逾3% 机构料公司销售收入可能逊于市场预期 去年收入及股东净利被下调
智通财经 · 02-25
港股异动 | 海吉亚医疗(06078)跌逾3% 机构料公司销售收入可能逊于市场预期 去年收入及股东净利被下调
患者未患癌被切胆囊埋化疗泵化疗三次，湘雅二医院被判赔57万余元
观察者网 · 02-22
患者未患癌被切胆囊埋化疗泵化疗三次，湘雅二医院被判赔57万余元
野村：维持海吉亚医疗“买入”评级 降目标价至34.81港元
新浪网 · 02-21
野村：维持海吉亚医疗“买入”评级 降目标价至34.81港元
野村：维持海吉亚医疗(06078)“买入”评级 降目标价至34.81港元
智通财经 · 02-21
野村：维持海吉亚医疗(06078)“买入”评级 降目标价至34.81港元
海吉亚医疗大涨超13% 股价创3个月新高
市场资讯 · 02-20
海吉亚医疗大涨超13% 股价创3个月新高
港股概念追踪|国内各大医院纷纷引进AI大模型 企业有望借助AI进一步提高竞争优势（附概念股）
智通财经 · 02-20
港股概念追踪|国内各大医院纷纷引进AI大模型 企业有望借助AI进一步提高竞争优势（附概念股）
【港股异动 | 海吉亚医疗(06078.HK)涨超10%】海吉亚医疗(06078.HK)涨超10%，截至发稿，涨10.53%，报17.42港元，成交额4.12亿港元。
金融界 · 02-20
【港股异动 | 海吉亚医疗(06078.HK)涨超10%】海吉亚医疗(06078.HK)涨超10%，截至发稿，涨10.53%，报17.42港元，成交额4.12亿港元。
港股异动 | 海吉亚医疗(06078)涨超10% 机构看好公司较高的内生增长能见度
智通财经 · 02-20
港股异动 | 海吉亚医疗(06078)涨超10% 机构看好公司较高的内生增长能见度
加载更多
公司概况
公司名称：
海吉亚医疗
所属市场：
SEHK
上市日期：
--
主营业务：
海吉亚医疗控股有限公司是一家主要从事肿瘤医疗业务的中国投资控股公司。通过其子公司，该公司主要运营三个业务部门。医院业务部门通过自己的医院为患者提供门诊和住院服务。放疗业务部门提供放射治疗中心咨询服务，以及放射治疗设备的租赁，销售，处置以及售后维修和保养服务。医院托管业务部门向其他医院提供与管理相关的服务。该公司在国内市场开展业务。
发行价格：
--
{"stockData":{"symbol":"06078","market":"HK","secType":"STK","nameCN":"海吉亚医疗","latestPrice":14.04,"timestamp":1742890083019,"preClose":14.42,"halted":0,"volume":3740800,"delay":0,"floatShares":622000000,"shares":622000000,"eps":1.158068980430878,"marketStatus":"未开盘","change":-0.38,"latestTime":"03-25 16:08:03","open":14.42,"high":14.42,"low":13.96,"amount":52681128,"amplitude":0.0319,"askPrice":14.04,"askSize":39200,"bidPrice":14.02,"bidSize":8400,"shortable":3,"etf":0,"ttmEps":1.241433303053156,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1742952600000},"marketStatusCode":0,"adr":0,"listingDate":1593360000000,"exchange":"SEHK","adjPreClose":14.42,"dividendRate":0.011533,"openAndCloseTimeList":[[1742866200000,1742875200000],[1742878800000,1742889600000]],"volumeRatio":0.45133,"lotSize":200,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/06078","defaultTab":"news","newsList":[{"id":"2518746857","title":"云顶新耀：新型mRNA个性化肿瘤治疗性疫苗EVM16完成首例患者给药","url":"https://stock-news.laohu8.com/highlight/detail?id=2518746857","media":"证券日报","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2518746857?lang=zh_cn&edition=full","pubTime":"2025-03-11 20:40","pubTimestamp":1741696802,"startTime":"0","endTime":"0","summary":"本报讯（记者张文湘见习记者金婉霞）3月10日，记者从云顶新耀医药科技有限公司（以下简称“云顶新耀”）获悉，公司自主研发的新型mRNA个性化肿瘤治疗性疫苗EVM16完成首例患者给药。值得一提的是，该疫苗的抗原由AI算法辅助完成开发。“云顶新耀自主研发了‘妙算’AI系统。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202503113342661684.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1161","BK1209","BK1574","LU2488822045.USD","01952","BK1583","LU0737861772.HKD","06078","LU0329678337.USD","LU0329678170.USD"],"gpt_icon":1},{"id":"2517271771","title":"海吉亚医疗盘中异动 下午盘大幅下挫5.04%报15.080港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2517271771","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2517271771?lang=zh_cn&edition=full","pubTime":"2025-03-07 14:26","pubTimestamp":1741328766,"startTime":"0","endTime":"0","summary":"2025年03月07日下午盘14时26分，海吉亚医疗股票出现异动，股价快速跳水5.04%。截至发稿，该股报15.080港元/股，成交量659.86万股，换手率1.06%，振幅5.04%。资金方面，该股资金流入3813.64万港元，流出4294.23万港元。海吉亚医疗股票所在的医疗及医学美容服务行业中，整体涨幅为0.46%。其相关个股中，讯飞医疗科技、瑞丽医美、德视佳涨幅较大，振幅较大的相关个股有瑞丽医美、现代健康科技、讯飞医疗科技，振幅分别为31.30%、17.20%、12.73%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250307142606abec831f&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250307142606abec831f&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU0737861772.HKD","LU0329678170.USD","BK1583","06078","LU0329678337.USD","BK1209","LU2488822045.USD"],"gpt_icon":0},{"id":"2517531159","title":"富达国际减持海吉亚医疗(06078)113.48万股 每股作价约16.83港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2517531159","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2517531159?lang=zh_cn&edition=full","pubTime":"2025-03-06 20:19","pubTimestamp":1741263559,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，香港联交所最新资料显示，2月27日，富达国际减持海吉亚医疗(06078)113.48万股，每股作价16.8258港元，总金额约为1909.39万港元。减持后最新持股数目为3674.96万股，最新持股比例为5.91%。本交易涉及其他关联方：Pandanus Associates Inc.和Pandanus Partners L.P.。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1258747.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["06078","YMM","LU0329678170.USD","BK4503","LU0456842615.SGD","BK1583","BK4526","BK4022","LU0327786744.USD","LU0737861772.HKD","LU0572944931.SGD","BK4539","LU0329678337.USD","BK1209","LU0455707207.USD","LU2488822045.USD","BK4232","LU0502904849.HKD","LU2242644610.SGD","BK4548"],"gpt_icon":0},{"id":"2517134455","title":"云顶新耀首款AI驱动的自研mRNA肿瘤治疗性疫苗完成首例患者给药","url":"https://stock-news.laohu8.com/highlight/detail?id=2517134455","media":"人民财讯","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2517134455?lang=zh_cn&edition=full","pubTime":"2025-03-06 17:38","pubTimestamp":1741253933,"startTime":"0","endTime":"0","summary":"人民财讯3月6日电，3月6日，云顶新耀宣布，公司自主研发的首款新型mRNA个性化肿瘤治疗性疫苗EVM16已在北京大学肿瘤医院顺利完成首例患者给药，表明云顶新耀具有自主知识产权的肿瘤新抗原人工智能（AI）算法系统和经过临床验证的mRNA技术平台已成功进入人体试验阶段。EVM16是一款云顶新耀自研、AI算法驱动识别肿瘤新抗原的新型mRNA个性化肿瘤治疗性疫苗。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202503063338618918.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1161","BK1209","BK1574","LU2488822045.USD","01952","BK1583","LU0737861772.HKD","06078","LU0329678337.USD","LU0329678170.USD"],"gpt_icon":0},{"id":"2517136565","title":"云顶新耀(01952)宣布首款自主研发的新型mRNA个性化肿瘤治疗性疫苗EVM16完成首例患者给药","url":"https://stock-news.laohu8.com/highlight/detail?id=2517136565","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2517136565?lang=zh_cn&edition=full","pubTime":"2025-03-06 16:57","pubTimestamp":1741251453,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，3月6日，云顶新耀宣布自主研发的首款新型mRNA个性化肿瘤治疗性疫苗EVM16已在北京大学肿瘤医院顺利完成首例患者给药，标志着此项临床试验项目的里程碑进展。EVM16是一款云顶新耀自研、AI算法驱动识别肿瘤新抗原的新型mRNA个性化肿瘤治疗性疫苗。个性化mRNA肿瘤疫苗则成为极具潜力的新一代免疫疗法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1258568.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["06078","BK1161","LU2488822045.USD","BK1209","BK1574","LU0329678337.USD","LU0737861772.HKD","159646","BK1583","01952","LU0329678170.USD"],"gpt_icon":0},{"id":"2517909842","title":"海吉亚医疗盘中异动 股价大涨5.04%","url":"https://stock-news.laohu8.com/highlight/detail?id=2517909842","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2517909842?lang=zh_cn&edition=full","pubTime":"2025-03-06 11:35","pubTimestamp":1741232139,"startTime":"0","endTime":"0","summary":"2025年03月06日临近午盘11时35分，海吉亚医疗股票出现异动，股价快速拉升5.04%。截至发稿，该股报15.840港元/股，成交量445.66万股，换手率0.72%，振幅3.58%。海吉亚医疗股票所在的医疗及医学美容服务行业中，整体涨幅为0.76%。其相关个股中，医脉通、固生堂、医渡科技涨幅较大，振幅较大的相关个股有梅斯健康、中国生物科技服务、医脉通，振幅分别为24.58%、17.78%、17.48%。海吉亚医疗公司简介：海吉亚医疗控股有限公司是一家主要从事医疗服务的公司。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250306113539963b9b82&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250306113539963b9b82&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU2488822045.USD","LU0329678337.USD","LU0329678170.USD","LU0737861772.HKD","BK1583","BK1209","06078"],"gpt_icon":0},{"id":"2516622481","title":"我国科研团队提出人工合成细菌治疗肿瘤新方法","url":"https://stock-news.laohu8.com/highlight/detail?id=2516622481","media":"美港电讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2516622481?lang=zh_cn&edition=full","pubTime":"2025-03-04 19:26","pubTimestamp":1741087566,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.ushknews.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_meigang","symbols":["06078","LU0737861772.HKD","BK1583","BK1209","LU0329678170.USD","LU2488822045.USD","LU0329678337.USD"],"gpt_icon":0},{"id":"2516152207","title":"海吉亚医疗盘中异动 快速拉升5.01%","url":"https://stock-news.laohu8.com/highlight/detail?id=2516152207","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2516152207?lang=zh_cn&edition=full","pubTime":"2025-03-03 09:53","pubTimestamp":1740966793,"startTime":"0","endTime":"0","summary":"2025年03月03日早盘09时53分，海吉亚医疗股票出现异动，股价大幅上涨5.01%。截至发稿，该股报15.500港元/股，成交量184.3万股，换手率0.30%，振幅4.74%。海吉亚医疗股票所在的医疗及医学美容服务行业中，整体跌幅为0.17%。其相关个股中，固生堂、医渡科技、医脉通涨幅较大，振幅较大的相关个股有固生堂、医思健康、医脉通，振幅分别为6.76%、5.71%、5.57%。海吉亚医疗公司简介：海吉亚医疗控股有限公司是一家主要从事医疗服务的公司。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202503030953139636ca68&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202503030953139636ca68&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU0737861772.HKD","LU0329678337.USD","LU2488822045.USD","BK1209","BK1583","06078","LU0329678170.USD"],"gpt_icon":0},{"id":"2514398492","title":"港股异动 | 海吉亚医疗(06078)再跌超7% 机构预计公司24年下半年销售收入或逊于市场预期","url":"https://stock-news.laohu8.com/highlight/detail?id=2514398492","media":"智通财经","labels":["dataReport","movement"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2514398492?lang=zh_cn&edition=full","pubTime":"2025-02-28 11:50","pubTimestamp":1740714600,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，海吉亚医疗再跌超7%，截至发稿，跌7.21%，报15.44港元，成交额1.17亿港元。中泰国际发布研报称，近期审视了海吉亚医疗2024年下半年营运情况，预计由于终端患者消费能力偏弱及医保控费趋严等原因，下半年销售收入可能逊于市场预期，将2024 年收入与股东净利润预测分别下调6.5%与7.5%。该行指出，海吉亚旗下的医院中，部分位于医保基金相对不足的三四线地区，预计短期内这些地区的医院经营仍受影响。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1255988.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,movement","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["06078","BK1209","LU0329678337.USD","BK1583","LU2488822045.USD","LU0737861772.HKD","LU0329678170.USD"],"gpt_icon":0},{"id":"2514099369","title":"海吉亚医疗盘中异动 早盘快速下跌5.05%","url":"https://stock-news.laohu8.com/highlight/detail?id=2514099369","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2514099369?lang=zh_cn&edition=full","pubTime":"2025-02-28 09:42","pubTimestamp":1740706960,"startTime":"0","endTime":"0","summary":"2025年02月28日早盘09时42分，海吉亚医疗股票出现波动，股价急速下跌5.05%。截至发稿，该股报15.800港元/股，成交量197万股，换手率0.32%，振幅3.61%。海吉亚医疗股票所在的医疗及医学美容服务行业中，整体跌幅为0.02%。其相关个股中，雍禾医疗、瑞丽医美、德视佳涨幅较大，振幅较大的相关个股有雍禾医疗、平安好医生、瑞尔集团，振幅分别为11.58%、5.52%、5.07%。海吉亚医疗公司简介：海吉亚医疗控股有限公司是一家主要从事医疗服务的公司。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025022809424096333e55&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025022809424096333e55&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["06078","LU0737861772.HKD","BK1583","LU0329678170.USD","BK1209","LU0329678337.USD","LU2488822045.USD"],"gpt_icon":0},{"id":"2514818522","title":"【首个自研ADC澳洲临床入组 康方生物IO 2+ADC战略再进一步】近日，康方生物宣布，公司自主研发的差异化靶向人表皮生长因子受体3（HER3）ADC新药AK138D1，治疗晚期恶性肿瘤的I期临床研究在澳洲完成首例受试者入组。AK138D1是康方生物首个进入临床阶段的ADC药物。ADC药物是康方生物在全球范围内重塑治疗格局，构建肿瘤治疗新标准，以创新疗法造福全球患者的重要力量，也是康方生物推进“IO 2.0+ADC”战略的重要抓手。目前康方生物自主研发的全球首创双抗新药卡度尼利（PD-1/CTLA-4双抗）和依沃西（PD-1/VEGF双抗）均已获批上市。康方生物是全球唯一拥有2个肿瘤免疫治疗双抗的制药公司，在IO+ADC联合战略中已经建立了在肿瘤免疫端的全球领先优势。AK138D1等差异化ADC药物的开发，为康方生物充分挖掘创新产品组合的临床价值，持续迭代肿瘤疗法开拓了更广阔的空间。","url":"https://stock-news.laohu8.com/highlight/detail?id=2514818522","media":"金融界","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2514818522?lang=zh_cn&edition=full","pubTime":"2025-02-27 08:40","pubTimestamp":1740616816,"startTime":"0","endTime":"0","summary":"AK138D1是康方生物首个进入临床阶段的ADC药物。ADC药物是康方生物在全球范围内重塑治疗格局，构建肿瘤治疗新标准，以创新疗法造福全球患者的重要力量，也是康方生物推进“IO 2.0+ADC”战略的重要抓手。康方生物是全球唯一拥有2个肿瘤免疫治疗双抗的制药公司，在IO+ADC联合战略中已经建立了在肿瘤免疫端的全球领先优势。AK138D1等差异化ADC药物的开发，为康方生物充分挖掘创新产品组合的临床价值，持续迭代肿瘤疗法开拓了更广阔的空间。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/02/27084048415964.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["BK1583","PD","09926","BK4231","BK1209","IE00B5MMRT66.SGD","LU0417516571.SGD","LU1794554557.SGD","ADC","LU1720050803.USD","LU0348783233.USD","BK4023","BK1574","LU0329678170.USD","LU2488822045.USD","LU0329678337.USD","LU1169590202.USD","IE00B543WZ88.USD","01477","BK4080","LU0348784397.USD","IE00BPRC5H50.USD","06078","BK1191","BK1161","LU1169589451.USD","LU0737861772.HKD"],"gpt_icon":0},{"id":"2514016081","title":"【港股异动 | 海吉亚医疗(06078.HK)跌逾3% 】海吉亚医疗(06078.HK)跌逾3%。截至发稿，跌2.36%，报16.52港元，成交额1595.27万港元。","url":"https://stock-news.laohu8.com/highlight/detail?id=2514016081","media":"金融界","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2514016081?lang=zh_cn&edition=full","pubTime":"2025-02-25 09:43","pubTimestamp":1740447828,"startTime":"0","endTime":"0","summary":"海吉亚医疗(06078.HK)跌逾3%。截至发稿，跌2.36%，报16.52港元，成交额1595.27万港元。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/02/25094348362199.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["06078","LU0737861772.HKD","BK1209","BK1583","LU2488822045.USD","LU0329678170.USD","LU0329678337.USD"],"gpt_icon":0},{"id":"2514081498","title":"港股异动 | 海吉亚医疗(06078)跌逾3% 机构料公司销售收入可能逊于市场预期 去年收入及股东净利被下调","url":"https://stock-news.laohu8.com/highlight/detail?id=2514081498","media":"智通财经","labels":["dataReport","movement"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2514081498?lang=zh_cn&edition=full","pubTime":"2025-02-25 09:37","pubTimestamp":1740447438,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，海吉亚医疗跌逾3%。中泰国际发布研报称，近期审视了海吉亚医疗2024年下半年营运情况，预计由于终端患者消费能力偏弱及医保控费趋严等原因，下半年销售收入可能逊于市场预期，该行将2024年收入与股东净利润预测分别下调6.5%与7.5%。海吉亚旗下的医院中，部分位于医保基金相对不足的三四线地区，预计短期内这些地区的医院经营仍受影响。考虑上述情况，该行将2025-26E的收入预测分别下调5.3%、5.7%，股东净利润预测下调7.4%、8.3%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1253799.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"港股异动 | 海吉亚医疗(06078)跌逾3% 机构料公司销售收入可能逊于市场预期 去年收入及股东净利被下调","news_tag":"dataReport,movement","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU0737861772.HKD","LU0329678170.USD","BK1209","LU2488822045.USD","BK1583","06078","LU0329678337.USD"],"gpt_icon":0},{"id":"2513299227","title":"患者未患癌被切胆囊埋化疗泵化疗三次，湘雅二医院被判赔57万余元","url":"https://stock-news.laohu8.com/highlight/detail?id=2513299227","media":"观察者网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2513299227?lang=zh_cn&edition=full","pubTime":"2025-02-22 16:05","pubTimestamp":1740211500,"startTime":"0","endTime":"0","summary":"长沙浏阳的张先生与中南大学湘雅二医院的一场民事诉讼近日落槌，湘雅二医院应该为该院医生的诊疗过错担责，赔偿张先生因该院诊疗行为产生的全部损失共计57万余元。目前，湘雅二院已履行判决赔偿款项。湘雅二医院将病情告知患者家属，家属表示拒绝肿块切除术，要求术中化疗，门静脉化疗泵埋置。术后，张先生前往湘雅二医院进行三次化疗，三次化疗医疗费总额为14275.95元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/roll/2025-02-22/doc-inemizmm2269069.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["06078","LU0329678170.USD","LU2488822045.USD","LU0737861772.HKD","BK1209","BK1583","LU0329678337.USD"],"gpt_icon":0},{"id":"2513238767","title":"野村：维持海吉亚医疗“买入”评级 降目标价至34.81港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2513238767","media":"新浪网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2513238767?lang=zh_cn&edition=full","pubTime":"2025-02-21 11:53","pubTimestamp":1740110000,"startTime":"0","endTime":"0","summary":"野村发布研报称，维持海吉亚医疗“买入”评级，目标价从50.7港元下调31%至34.81港元，反映95%的上涨空间。预计下半年至2024年有机增长将略有加快，但因现有医院表现弱于预期、新医院扩张放缓，将2024/25财年收入和盈利预测下调6.4%及14.7%，并将2024/25财年盈利预测下调4.5%及13.1%。和讯网站对文中陈述、观点判断保持中立，不对所包含内容的准确性、可靠性或完整性提供任何明示或暗示的保证。请读者仅作参考，并请自行承担全部责任。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250221123909988d3439&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250221123909988d3439&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["06078"],"gpt_icon":0},{"id":"2513284600","title":"野村：维持海吉亚医疗(06078)“买入”评级 降目标价至34.81港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2513284600","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2513284600?lang=zh_cn&edition=full","pubTime":"2025-02-21 10:53","pubTimestamp":1740106408,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，野村发布研报称，维持海吉亚医疗(06078)“买入”评级，目标价从50.7港元下调31%至34.81港元，反映95%的上涨空间。预计下半年至2024年有机增长将略有加快，但因现有医院表现弱于预期、新医院扩张放缓，将2024/25财年收入和盈利预测下调6.4%及14.7%，并将2024/25财年盈利预测下调4.5%及13.1%。在此之前，该行预计该公司将在2025财年收购一家医院，但考虑到公司的现金状况和当前股价(尽管最近股价有所反弹)，预计该公司将不会收购医院。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1252566.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["06078"],"gpt_icon":0},{"id":"2512499458","title":"海吉亚医疗大涨超13% 股价创3个月新高","url":"https://stock-news.laohu8.com/highlight/detail?id=2512499458","media":"市场资讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2512499458?lang=zh_cn&edition=full","pubTime":"2025-02-20 14:33","pubTimestamp":1740033180,"startTime":"0","endTime":"0","summary":"海吉亚医疗（6078.HK）大幅上涨超13%，高见18.14港元创3个月新高价，成交额放大至5.94亿港元，总市值110亿港元。\n 消息上，据悉，截至2024年，海吉亚医疗已运营和管理的医院数量达到16家，其中拥有4家三级综合医院。并且，公司以肿瘤治疗为核心，接入大模型或者自身训练驱动专科大模型能够快速赋能或接入所有医院，收效较高。\n 中银证券指出，医药+AI前景可期。该行认为，AI在诊断及诊断和疾病检测中展现出较大潜力。瑞银认为，市场忽略了海吉亚医疗因市场整合所带来的长期机会，因此该股当前的估值偏低。\n\n\n\n海量资讯、精准解读，尽在新浪财经APP\n\n责任编辑：张倩","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/bxjj/2025-02-20/doc-inemchxh4690427.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["LU2488822045.USD","LU0329678337.USD","LU0329678170.USD","06078","BK1583","LU0737861772.HKD","BK1209"],"gpt_icon":0},{"id":"2512328493","title":"港股概念追踪|国内各大医院纷纷引进AI大模型 企业有望借助AI进一步提高竞争优势（附概念股）","url":"https://stock-news.laohu8.com/highlight/detail?id=2512328493","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2512328493?lang=zh_cn&edition=full","pubTime":"2025-02-20 13:39","pubTimestamp":1740029952,"startTime":"0","endTime":"0","summary":"2月13日，北京儿童医院多学科会诊引入全国首个“AI儿科医生”，这是该院儿童健康人工智能大模型系列产品之一，整合了300多位知名儿科专家临床经验和数十年的高质量病历数据，通过结构化临床推理范式训练驱动而成，其具备强大的临床推理能力。AI虚拟医生能够解决的痛点有哪些？公司净利润受旗下医院变动影响波动较大，预计随着旗下医院及结构进入稳定运营期，净利润有望企底回升进入快速成长阶段。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1252069.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1209","LU2488822045.USD","HSCEI","06078","LU0329678337.USD","HSTECH","BK1583","BK1570","LU0737861772.HKD","LU0329678170.USD","01515","YANG"],"gpt_icon":1},{"id":"2512462876","title":"【港股异动 | 海吉亚医疗(06078.HK)涨超10%】海吉亚医疗(06078.HK)涨超10%，截至发稿，涨10.53%，报17.42港元，成交额4.12亿港元。","url":"https://stock-news.laohu8.com/highlight/detail?id=2512462876","media":"金融界","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2512462876?lang=zh_cn&edition=full","pubTime":"2025-02-20 12:02","pubTimestamp":1740024155,"startTime":"0","endTime":"0","summary":"海吉亚医疗(06078.HK)涨超10%，截至发稿，涨10.53%，报17.42港元，成交额4.12亿港元。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/02/20120248274841.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["LU0737861772.HKD","LU0329678337.USD","LU2488822045.USD","BK1209","BK1583","06078","LU0329678170.USD"],"gpt_icon":0},{"id":"2512464123","title":"港股异动 | 海吉亚医疗(06078)涨超10% 机构看好公司较高的内生增长能见度","url":"https://stock-news.laohu8.com/highlight/detail?id=2512464123","media":"智通财经","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2512464123?lang=zh_cn&edition=full","pubTime":"2025-02-20 11:56","pubTimestamp":1740023818,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，海吉亚医疗涨超10%，截至发稿，涨10.53%，报17.42港元，成交额4.12亿港元。按要求，今年全国80%左右统筹地区基本实现基本医保基金与定点医药机构即时结算。此外，中银证券指出，医药+AI前景可期。该行认为，AI在诊断及诊断和疾病检测中展现出较大潜力。该行看好海吉亚医疗较高的内生增长能见度，以及新院区建成落地后的业绩增量贡献。瑞银认为，市场忽略了海吉亚医疗因市场整合所带来的长期机会，因此该股当前的估值偏低。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1252049.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["06078","LU0737861772.HKD","BK1583","LU0329678170.USD","BK1209","LU0329678337.USD","LU2488822045.USD"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.hygeia-group.com","stockEarnings":[{"period":"1week","weight":-0.0702},{"period":"1month","weight":-0.2103},{"period":"3month","weight":-0.0344},{"period":"6month","weight":-0.2077},{"period":"1year","weight":-0.4631},{"period":"ytd","weight":-0.0154}],"compareEarnings":[{"period":"1week","weight":-0.0564},{"period":"1month","weight":-0.0057},{"period":"3month","weight":0.1615},{"period":"6month","weight":0.1716},{"period":"1year","weight":0.4171},{"period":"ytd","weight":0.1637}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"海吉亚医疗控股有限公司是一家主要从事肿瘤医疗业务的中国投资控股公司。通过其子公司，该公司主要运营三个业务部门。医院业务部门通过自己的医院为患者提供门诊和住院服务。放疗业务部门提供放射治疗中心咨询服务，以及放射治疗设备的租赁，销售，处置以及售后维修和保养服务。医院托管业务部门向其他医院提供与管理相关的服务。该公司在国内市场开展业务。","yearOnYearQuotes":[{"month":1,"riseRate":0.4,"avgChangeRate":-0.067938},{"month":2,"riseRate":0.6,"avgChangeRate":0.079436},{"month":3,"riseRate":0.4,"avgChangeRate":-0.053222},{"month":4,"riseRate":1,"avgChangeRate":0.099212},{"month":5,"riseRate":0.75,"avgChangeRate":0.101295},{"month":6,"riseRate":0.5,"avgChangeRate":0.029682},{"month":7,"riseRate":0.4,"avgChangeRate":-0.048777},{"month":8,"riseRate":0.2,"avgChangeRate":-0.056233},{"month":9,"riseRate":0.8,"avgChangeRate":0.091895},{"month":10,"riseRate":0.6,"avgChangeRate":-0.040072},{"month":11,"riseRate":0.6,"avgChangeRate":0.054421},{"month":12,"riseRate":0.2,"avgChangeRate":-0.086241}],"exchange":"SEHK","name":"海吉亚医疗","nameEN":"HYGEIA HEALTH"},"APP":{"userAgent":"CCBot/2.0 (https://commoncrawl.org/faq/)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.32.1","shortVersion":"4.32.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"海吉亚医疗(06078)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供海吉亚医疗(06078)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"海吉亚医疗,06078,海吉亚医疗股票,海吉亚医疗股票老虎,海吉亚医疗股票老虎国际,海吉亚医疗行情,海吉亚医疗股票行情,海吉亚医疗股价,海吉亚医疗股市,海吉亚医疗股票价格,海吉亚医疗股票交易,海吉亚医疗股票购买,海吉亚医疗股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"海吉亚医疗(06078)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供海吉亚医疗(06078)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}